Literature DB >> 25583389

Immaturity of human stem-cell-derived cardiomyocytes in culture: fatal flaw or soluble problem?

Christiaan C Veerman1, Georgios Kosmidis, Christine L Mummery, Simona Casini, Arie O Verkerk, Milena Bellin.   

Abstract

Cardiomyocytes from human pluripotent stem cells (hPSC-CMs) are increasingly used to model cardiac disease, test drug efficacy and for safety pharmacology. Nevertheless, a major hurdle to more extensive use is their immaturity and similarity to fetal rather than adult cardiomyocytes. Here, we provide an overview of the strategies currently being used to increase maturation in culture, which include prolongation of time in culture, exposure to electrical stimulation, application of mechanical strain, growth in three-dimensional tissue configuration, addition of non-cardiomyocytes, use of hormones and small molecules, and alteration of the extracellular environment. By comparing the outcomes of these studies, we identify the approaches most likely to improve functional maturation of hPSC-CMs in terms of their electrophysiology and excitation-contraction coupling.

Entities:  

Mesh:

Year:  2015        PMID: 25583389     DOI: 10.1089/scd.2014.0533

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  99 in total

Review 1.  Electrical and mechanical stimulation of cardiac cells and tissue constructs.

Authors:  Whitney L Stoppel; David L Kaplan; Lauren D Black
Journal:  Adv Drug Deliv Rev       Date:  2015-07-30       Impact factor: 15.470

2.  Stem cells: The cancer's gone, but did chemotherapy damage your heart?

Authors:  Milena Bellin; Christine L Mummery
Journal:  Nat Rev Cardiol       Date:  2016-05-26       Impact factor: 32.419

3.  Proteasome-Dependent Regulation of Distinct Metabolic States During Long-Term Culture of Human iPSC-Derived Cardiomyocytes.

Authors:  Antje Ebert; Amit U Joshi; Sandra Andorf; Yuanyuan Dai; Shrivatsan Sampathkumar; Haodong Chen; Yingxin Li; Priyanka Garg; Karl Toischer; Gerd Hasenfuss; Daria Mochly-Rosen; Joseph C Wu
Journal:  Circ Res       Date:  2019-05-20       Impact factor: 17.367

4.  DNA damage-free iPS cells exhibit potential to yield competent cardiomyocytes.

Authors:  Jessica M Miller; Nikhil M Mardhekar; Danielle Pretorius; Prasanna Krishnamurthy; Namakkal Soorappan Rajasekaran; Jianyi Zhang; Ramaswamy Kannappan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-02-14       Impact factor: 4.733

Review 5.  Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine.

Authors:  Nazish Sayed; Chun Liu; Joseph C Wu
Journal:  J Am Coll Cardiol       Date:  2016-05-10       Impact factor: 24.094

Review 6.  Towards chamber specific heart-on-a-chip for drug testing applications.

Authors:  Yimu Zhao; Naimeh Rafatian; Erika Yan Wang; Qinghua Wu; Benjamin F L Lai; Rick Xingze Lu; Houman Savoji; Milica Radisic
Journal:  Adv Drug Deliv Rev       Date:  2020-01-07       Impact factor: 15.470

Review 7.  Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as Models for Cardiac Channelopathies: A Primer for Non-Electrophysiologists.

Authors:  Priyanka Garg; Vivek Garg; Rajani Shrestha; Michael C Sanguinetti; Timothy J Kamp; Joseph C Wu
Journal:  Circ Res       Date:  2018-07-06       Impact factor: 17.367

Review 8.  Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes: a Critical Step for Drug Development and Cell Therapy.

Authors:  Shi Hua Tan; Lei Ye
Journal:  J Cardiovasc Transl Res       Date:  2018-03-19       Impact factor: 4.132

Review 9.  Tissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screening.

Authors:  Yosuke K Kurokawa; Steven C George
Journal:  Adv Drug Deliv Rev       Date:  2015-07-23       Impact factor: 15.470

Review 10.  Will iPSC-cardiomyocytes revolutionize the discovery of drugs for heart disease?

Authors:  Arne An Bruyneel; Wesley L McKeithan; Dries Am Feyen; Mark Mercola
Journal:  Curr Opin Pharmacol       Date:  2018-08-03       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.